HomeAbout Board of Directors

Board of Directors
2020 - 2021

Officers

  • President

    Gennady Bratslavsky, MD Show More
    SUNY Upstate Urology
    750 E Adams St
    Syracuse, NY 13210-2306
  • Secretary/Treasurer

    Michael Edward Woods, MD, FACS Show More
    Loyola University Medical Center
    Urology - Fahey Building
    2160 S. 1st Ave.
    Maywood, IL 60153-3328
  • Past President

    Robert Guy Uzzo, MD MBA FACS Show More
    Temple Fox Chase Cancer Center
    Department of Surgery
    333 Cottman Ave. RM. C302
    Philadelphia, PA 19111

Directors (Ex-Officio) SUO President, President-Elect, Secretary, & Treasurer

  • Director

    Michael S. Cookson, MD, MMHC, FACS Show More
    University of Oklahoma
    Health Sciences Center-Dept. of Urology
    920 Stanton L. Young Blvd.
    WP 2140
    Oklahoma City, OK 73104
    Michael S. Cookson, MD

    Michael S. Cookson, MD is Professor and Chairman of the Department of Urology at the University of Oklahoma Health Sciences Center, and holds the Donald D. Albers Endowed Chair in Urology. An accomplished researcher and lecturer, he is the author of 206 peer-reviewed journal publications and 28 chapters of various textbooks in urology and urologic surgery, and has been recognized nationally for his outstanding contributions to urologic oncology.

    Dr. Cookson completed his Urology residency at the University of Texas, San Antonio and completed his Urologic Oncology Fellowship at Memorial Sloan-Kettering Cancer Center in New York. He was a member of the faculty at Vanderbilt University from 1998 to 2013, where he served as the Vice Chairman of Urologic Surgery and Director of the Urologic Oncology Fellowship Program.

    Dr. Cookson has devoted a significant portion of his academic career to the management of patients with urologic cancers, with a strong emphasis on Clinical Guidelines, Education and Evidenced Based Medicine. He was a member of the AUA/ABU examination committee for 10 years, including a member of Task for Cancer, Oncology Consultant and Pathology editor. He also serves on the ABU Oral Examination Committee. He is a co-founder of the OKAT, an SUO mandated oncology examination that is the standard for benchmarking for members and oncology fellows in training and served as Chair of that OKAT committee for 5 years. In 2011, he received the President’s Distinguished Service Award from the SUO for educational contributions. For his efforts in teaching at Vanderbilt, he was awarded the Michael Rodriquez Award.

    Dr. Cookson recently served as the Chair of the AUA Guidelines Committee on Castration Resistant Prostate Cancer, and has previously served as the member of the AUA Guidelines on localized prostate cancer. He currently serves as Treasurer for the Society of Urologic Oncology.
  • Director

    Jeffrey Maxwell Holzbeierlein, MD, FACS Show More
    University of Kansas Health System
    3901 Rainbow Blvd
    Mail Stop 3016
    Kansas City, KS 66160
    Jeffrey Holzbeierlein, MD

    Dr. Jeffrey Holzbeierlein is the John W. Weigel Endowed Professor of Urology and the Director of Urologic Oncology at the University of Kansas Medical Center. He was raised in Edmond, Oklahoma and received his undergraduate degree from Vanderbilt University where he played for the men’s tennis team. He received his medical degree from the University of Oklahoma and joined the faculty at KU after completing his internship and residency at Vanderbilt University and a fellowship in Urologic Oncology at Memorial Sloan Kettering Cancer Center in New York.

    Dr. Holzbeierlein is a member of the Society of Urologic Oncology where he is the past Chair of the Fellowship Committee and serves on the Executive Board of the SUO. He is the President-Elect of the South Central Section of the American Urological Association and serves on the Board of Directors. He has served on the American Board of Urology Examination Committee and is currently and Oral Examiner for the Board Exams. He is a past Assistant Editor for the Journal of Urology. Dr. Holzbeierein has served on numerous AUA Committees including: the Practice Guidelines Committee and the Public Media Committee and has completed the AUA Leadership Program. In addition, he is a Fellow of the American College of Surgeons and serves on the Kansas selection board. Dr. Holzbeierlein is also the past Chair and founding member of the Young Urologic Oncologists Section of the Society of Urologic Oncology. He is a reviewer for the Journal of Urology, Practical Reviews in Urology, Cancer, and Urologic Oncology. He was recently awarded the Resident Mentoring Award for faculty at the University of Kansas Hospital.

    Dr. Holzbeierlein serves on numerous hospital committees including the University of Kansas Physicians Board of Directors, the Promotions and Tenure Committee, the Elections Committee for the School of Medicine, and the Board for the Kansas Tissue and Serum Repository. He is also co-director of the K-Inbre Translational Research Core, and the Director of the Genitourinary Disease Working Group. He is the Director of the Burns and McDonnell High Risk Prostate Cancer Prevention and Survivorship Clinic at the University of Kansas Cancer Center.

    Dr. Holzbeierlein has published numerous peer reviewed journal articles, and has numerous presentation and abstracts in journals and textbooks dealing with urologic oncology. He has been an annual lecturer for an AUA Course focusing on the Management of High Risk Superficial Bladder Cancer which was selected as one of the “best courses” at the AUA. He has intramural and extramural grant support including a co-investigator on an R01, and as PI on several investigator initiated trials and Pharma trials.

    Dr. Holzbeierlein specializes in the treatment of genitourinary malignancies including prostate, bladder, kidney, testicular, and penile cancers. His research interest includes the androgen receptor as a target of Hsp90 inhibitors in prostate cancer and clinically decreasing the morbidity associated with cystectomy. He lives in Kansas City with his wife Jill and their 4 children, and is civically active at the Hope Lodge of Kansas City and Maisson deNaissance.
  • Director

    Adam Stuart Kibel, MD Show More
    Brigham and Women's Hospital
    45 Francis Street
    Division of Urology
    Boston, MA 02115
  • Director

    Daniel W. Lin, MD Show More
    University of Washington
    Department of Urology
    1959 NE Pacific, BB1106 B
    Campus Box 356510
    Seattle, WA 98195

  • NIH Liaison

    W. Marston Linehan, MD Show More
    Urologic Oncology Branch - National Cancer Institute
    NIH/NCI Urologic Oncology
    10 Ct. Dr. Rm. 1W-5940
    Bethesda, MD 20892-1107
    W. Marston Linehan, MD

    W. Marston Linehan, MD is Chief of Urologic Surgery and the Urologic Oncology Branch, Center for Cancer Research, at the National Cancer Institute, National Institutes of Health, Bethesda, Maryland. He has had a long standing interest in identification of the genetic basis of cancer of the kidney. By studying families with kidney cancer, he and his colleagues identified the VHL gene (von Hippel Lindau, clear cell renal carcinoma), the gene for Hereditary Papillary Renal Carcinoma (c-Met oncogene, type I papillary renal carcinoma) and the BHD gene (Birt Hogg Dubé syndrome, chromophobe renal carcinoma) and described the germline fumarate hydratase mutations in the North American families with hereditary leiomyomatosis renal cell carcinoma (HLRCC). This work has provided the basis for the development of new therapeutic strategies for the different types of kidney cancer based on understanding the molecular pathway of the specific cancer genes associated with the different types of kidney cancer. He and his colleagues have defined the methods for clinical management of kidney cancer associated with the hereditary forms of kidney cancer, von Hippel Lindau, Hereditary Papillary Renal Carcinoma and Birt Hogg Dubé syndrome and HLRCC.

    Dr. Linehan has published more than 480 manuscripts and is currently on the editorial board of 7 journals. He has received numerous honors including the NIH Director’s Award for discovery of the VHL kidney cancer gene, the Gold Cystoscope Award and the Distinguished Contribution Award from the American Urological Association, the SUO Medal from the Society of Urologic Oncology, the Dr. Nathan Davis Award from the American Medical Association and the Barringer Medal from the American Association of Genitourinary Surgeons. He is Past-President of the Society of Urologic Oncology.
  • YUO Representative

    Kelly L. Stratton, MD, FACS Show More
    University of Oklahoma
    920 Stanton L Young Blvd
    WP2140
    Department of Urology
    Oklahoma City, OK 73104

Headquarter Office

  • Executive Director

    Pam Murphy Show More
    WJWeiser & Associates, Inc.
    1100 E. Woodfield Road, Suite 350
    Schaumburg, IL 60173